Gyulladásos bélbetegségeket kíséró osteoporosis.

Translated title of the contribution: Osteoporosis associated with inflammatory bowel diseases

P. Miheller, Miklós Tóth, István Pregun, Z. Tulassay

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Inflammatory bowel diseases, most frequently Crohn's disease, are frequently accompanied by decreased bone mineral content (30-70%). The osteopenia is not explained by the side effects of treatment or the secondary malabsorption. There must be a common pathological pathway in the background. The mineral content of bones is most easily measured by dual-ray absorptiometry. The measurement should be performed at the time of the diagnosis of bowel disease. It is useful to perform some routine laboratory examinations (serum calcium and phosphate, urinary calcium excretion level, etc.) and some special tests (serum osteocalcin and crosslaps) to exclude some other pathological pathways as well as to plan the anti-osteoporotic therapy. Appropriate calcium and vitamin-D supplementation is essential in prevention and therapy as well. Several drug-classes have proven useful in the therapy of severe osteoporosis associated with inflammatory bowel diseases such as bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators and calcitonin. The authors provide an algorithm for the therapy of metabolic bone disease in inflammatory bowel disease.

Original languageHungarian
Pages (from-to)1045-1051
Number of pages7
JournalOrvosi Hetilap
Volume145
Issue number20
Publication statusPublished - May 16 2004

Fingerprint

Inflammatory Bowel Diseases
Osteoporosis
glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine
Metabolic Bone Diseases
Bone Density
Calcium
Selective Estrogen Receptor Modulators
Therapeutics
Osteocalcin
Hormone Replacement Therapy
Diphosphonates
Calcitonin
Serum
Vitamin D
Crohn Disease
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gyulladásos bélbetegségeket kíséró osteoporosis. / Miheller, P.; Tóth, Miklós; Pregun, István; Tulassay, Z.

In: Orvosi Hetilap, Vol. 145, No. 20, 16.05.2004, p. 1045-1051.

Research output: Contribution to journalArticle

Miheller, P, Tóth, M, Pregun, I & Tulassay, Z 2004, 'Gyulladásos bélbetegségeket kíséró osteoporosis.', Orvosi Hetilap, vol. 145, no. 20, pp. 1045-1051.
Miheller, P. ; Tóth, Miklós ; Pregun, István ; Tulassay, Z. / Gyulladásos bélbetegségeket kíséró osteoporosis. In: Orvosi Hetilap. 2004 ; Vol. 145, No. 20. pp. 1045-1051.
@article{31f8ee73bb404635b48613e66b9e6eb8,
title = "Gyullad{\'a}sos b{\'e}lbetegs{\'e}geket k{\'i}s{\'e}r{\'o} osteoporosis.",
abstract = "Inflammatory bowel diseases, most frequently Crohn's disease, are frequently accompanied by decreased bone mineral content (30-70{\%}). The osteopenia is not explained by the side effects of treatment or the secondary malabsorption. There must be a common pathological pathway in the background. The mineral content of bones is most easily measured by dual-ray absorptiometry. The measurement should be performed at the time of the diagnosis of bowel disease. It is useful to perform some routine laboratory examinations (serum calcium and phosphate, urinary calcium excretion level, etc.) and some special tests (serum osteocalcin and crosslaps) to exclude some other pathological pathways as well as to plan the anti-osteoporotic therapy. Appropriate calcium and vitamin-D supplementation is essential in prevention and therapy as well. Several drug-classes have proven useful in the therapy of severe osteoporosis associated with inflammatory bowel diseases such as bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators and calcitonin. The authors provide an algorithm for the therapy of metabolic bone disease in inflammatory bowel disease.",
author = "P. Miheller and Mikl{\'o}s T{\'o}th and Istv{\'a}n Pregun and Z. Tulassay",
year = "2004",
month = "5",
day = "16",
language = "Hungarian",
volume = "145",
pages = "1045--1051",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "20",

}

TY - JOUR

T1 - Gyulladásos bélbetegségeket kíséró osteoporosis.

AU - Miheller, P.

AU - Tóth, Miklós

AU - Pregun, István

AU - Tulassay, Z.

PY - 2004/5/16

Y1 - 2004/5/16

N2 - Inflammatory bowel diseases, most frequently Crohn's disease, are frequently accompanied by decreased bone mineral content (30-70%). The osteopenia is not explained by the side effects of treatment or the secondary malabsorption. There must be a common pathological pathway in the background. The mineral content of bones is most easily measured by dual-ray absorptiometry. The measurement should be performed at the time of the diagnosis of bowel disease. It is useful to perform some routine laboratory examinations (serum calcium and phosphate, urinary calcium excretion level, etc.) and some special tests (serum osteocalcin and crosslaps) to exclude some other pathological pathways as well as to plan the anti-osteoporotic therapy. Appropriate calcium and vitamin-D supplementation is essential in prevention and therapy as well. Several drug-classes have proven useful in the therapy of severe osteoporosis associated with inflammatory bowel diseases such as bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators and calcitonin. The authors provide an algorithm for the therapy of metabolic bone disease in inflammatory bowel disease.

AB - Inflammatory bowel diseases, most frequently Crohn's disease, are frequently accompanied by decreased bone mineral content (30-70%). The osteopenia is not explained by the side effects of treatment or the secondary malabsorption. There must be a common pathological pathway in the background. The mineral content of bones is most easily measured by dual-ray absorptiometry. The measurement should be performed at the time of the diagnosis of bowel disease. It is useful to perform some routine laboratory examinations (serum calcium and phosphate, urinary calcium excretion level, etc.) and some special tests (serum osteocalcin and crosslaps) to exclude some other pathological pathways as well as to plan the anti-osteoporotic therapy. Appropriate calcium and vitamin-D supplementation is essential in prevention and therapy as well. Several drug-classes have proven useful in the therapy of severe osteoporosis associated with inflammatory bowel diseases such as bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators and calcitonin. The authors provide an algorithm for the therapy of metabolic bone disease in inflammatory bowel disease.

UR - http://www.scopus.com/inward/record.url?scp=3242662036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242662036&partnerID=8YFLogxK

M3 - Article

C2 - 15202326

AN - SCOPUS:3242662036

VL - 145

SP - 1045

EP - 1051

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 20

ER -